BUDOTITANE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C10H9O2.2C2H5O.Ti
Molecular Weight	460.343
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	-4

SHOW SMILES / InChI

Structure Search

SMILES

[Ti].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C2=CC=CC=C2

InChI

InChIKey=KAPHMPHWLCJRRK-UHFFFAOYSA-N

InChI=1S/2C10H9O2.2C2H5O.Ti/c2*1-8(11)7-10(12)9-5-3-2-4-6-9;2*1-2-3;/h2*2-7H,1H3;2*2H2,1H3;/q4*-1;

HIDE SMILES / InChI

Molecular Formula	C10H10O2
Molecular Weight	162.1852
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Ti
Molecular Weight	47.867
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C2H5O
Molecular Weight	45.0605
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7988618 | https://www.ncbi.nlm.nih.gov/pubmed/8824351 | https://www.ncbi.nlm.nih.gov/pubmed/2032232 | https://www.ncbi.nlm.nih.gov/pubmed/2775338 | https://www.pharmacologicalsciences.us/anti-tumor/budotitane.html

Budotitane [cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium (IV)] is an inorganic titanium complex. The complex acts as a DNA intercalating agent thereby affecting cell proliferation. Preclinical studies in established screening models indicate considerable antitumor activity. Budotitane reached the end of phase I clinical trials for the treatment of solid tumors.

Approval Year

PubMed

Title	Date	PubMed
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.	1996	8824351
Complexes of metals other than platinum as antitumour agents.	1994	7988618
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.	1991-06-01	2032232
Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studies.	1989-06	2775338

Sample Use Guides

In Vivo Use Guide

Phase I trial dose levels ranged from 100 mg/m2 to 230 mg/m2 twice weekly. Using this schedule, 180 mg/m2 is a safe dose for subsequent clinical studies.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:05:07 GMT 2025` Edited by `admin` on `Wed Apr 02 07:05:07 GMT 2025`
Record UNII	DV05VZD83V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIETHOXYBIS(1-PHENYL-1,3-BUTANEDIONATO)TITANIUM

Preferred Name

English

BUDOTITANE

Official Name

English

budotitane [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C274